Xultophy® (IDegLira) approved in Europe
2014-09-18 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 18 September 2014 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Xultophy® for the treatment of type 2 diabetes mellitus in adults. The authorisation covers all 27 European Union member states. For further information Media: Mike Rulis +45 3079 3573 [email protected] Ken Inchausti (US) +1 609 514 8316 [email protected] Investors: Kasper Roseeuw Poulsen +45 3079 4303 [email protected] Jannick Lindegaard Denholt +45 3079 8519 [email protected] Daniel Bohsen +45 3079 6376 [email protected] Frank Daniel Mersebach (US) +1 609 235 8567 [email protected] Company announcement No 58 / 2014
The release as fetched from its publisher. novonordisk.com ↗